Ongoing pharmaceutical reforms in France: Implications for key stakeholder groups

Applied Health Economics and Health Policy

Volumn 8, Issue 1, 2010, Pages 7-24

  Sermet, Catherine ^a   Andrieu, Veronique ^b   Godman, Brian ^c,d,e   Van Ganse, Eric ^f   Haycox, Alan ^d   Reynier, Jean Pierre ^b  

^a Institut de Recherche et de Documentation en Economie de la Santé Irdes   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^d UNIVERSITY OF LIVERPOOL MANAGEMENT SCHOOL   (United Kingdom)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^f HOSPICES CIVILS DE LYON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIINFECTIVE AGENT; ANXIOLYTIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GENERIC DRUG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPNOTIC AGENT; PROTON PUMP INHIBITOR;

AMBULATORY CARE; DRUG COST; DRUG INDUSTRY; DRUG QUALITY; FRANCE; HEALTH CARE COST; HEALTH CARE QUALITY; HUMAN; NOTE; PRESCRIPTION; PUBLICATION; REIMBURSEMENT; RISK BENEFIT ANALYSIS;

BIOMEDICAL TECHNOLOGY; COST CONTROL; DRUG COSTS; DRUGS, GENERIC; FORMULARIES, HOSPITAL; FRANCE; HEALTH CARE REFORM; HUMANS; QUALITY ASSURANCE, HEALTH CARE;

EID: 74249104458     PISSN: 11755652     EISSN: 11791896     Source Type: Journal    
DOI: 10.1007/bf03256162     Document Type: Note

References (113)

1. Garattini L, Motterlini N, Cornago D. Prices and distribution margins of in-patent drugs in pharmacy: a comparison in seven European countries. Health Policy 2008; 85: 305-313
2. Organisation for Economic Co-operation and Development. OECD health data 2009: frequently requested data. Paris: OECD, 2009 [online]. Available viaURL: http://www. oecd.org/document/16/0,3343,en-2649-34631-2085200-1- 1-1-1,00.html [Accessed 2009 Nov 1]
3. L'Assurance Maladie. Chiffres & repères 2006 ed. [online]. Available from URL: http://www.ameli.fr/l-assurancemaladie/ statistiques-et- publications/points-de-repere/index. php [Accessed 2008 Jul 7]
4. Grandfils N, Sermet C. Pharmaceutical policy in France: a mosaic of reforms. Eurohealth 2006; 12 (3): 15-17
5. Degos L, Romaneix F, Michel P, et al. Can France keep its patients happy? BMJ 2008; 336: 254-257
6. Sabban C, Courtois J. Comparaisons européennes sur huit classes de médicaments. l'Assurance maladie. Points de repère décembre 2007-numéro 12 [online]. Available from URL: http://www.ameli.fr/fileadmin/user-upload/ documents/Points-de-repere-n--12.pdf [Accessed 2009 Feb 17]
7. l'Assurance Maladie. Ré sultats de l'enquête de satisfaction 2007: les assurés jugent la qualité des services de l'Assurance Maladie [online]. Available from URL: http:// www.ameli.fr/fileadmin/user- upload/documents/Enquete- assures.pdf [Accessed 2009 Jul 7]
8. European Observatory on Health Systems and Policies. Health care systems in transition: HiT summary. Copenhagen: European Observatory on Health Systems and Policies, WHO regional office for Europe, 2004 [online]. Available from URL: http://www.euro.who.int/document/ e83126sum.pdf [Accessed 2009Mar 6]
9. Cases C. French health system reform: recent implementation and future challenges. Eurohealth 2006; 12: 10-11
10. Coleman M, QuaresmaM, Berrino F, et al. Cancer survival in five continents: a worldwide population-based study (CONCORD). Lancet Oncol 2008; 9: 730-756
11. Björnberg A, Uhlir M. Eurohealth consumer index 2008 report. Brussels: Health Consumer Powerhouse AB, 2008 [online]. Available from URL: http://www.healthpower house.com/files/2008-EHCI/EHCI-2008-report.pdf [Accessed 2009 Mar 1]
12. Van Ganse E, Chamba G, Becquart B, et al. Pharmaceutical pricing and reimbursement information: France October 2007 [online]. Available from URL: http://ppri. oebig.at/Downloads/Results/France-PPRI-2007.pdf [Accessed 2009 Jan 20]
13. Kusnik-Joinville O, Weill A, Salanave B, et al. Prevalence and treatment of diabetes in France: trends between 2000 and 2005. Diabetes Metab 2008; 34: 266-272
14. Dufour C. La France, 10,5 millions d'hypertendus traits. L'Assurance Maladie, 2008 [online]. Available from URL: http://www.ameli.fr/fileadmin/user- upload/documents/AMD P-DP-HTA-VDEF1.pdf [Accessed 2008 Jul 7]
15. L'Assurance Maladie. Mieux utiliser les traitements anticholeste ́ rol: l'Assurance Maladie renforce son action pour favoriser le respect des recommandations sanitaires [online]. Available from URL: http://www.ameli.fr/ filead min/user-upload/documents/DP-Statines-vdef.pdf [Accessed 2008 Jul 7]
16. Grandfils N. Drug price setting and regulation in France [working paper DT no. 16]. Paris: IRDES, 2008 Sep [online]. Available from URL: http://www.irdes.fr/Espace Anglais/Publications/WorkingPapers/DT16DrugPriceSet tingRegulationFrance.pdf [Accessed 2008 Nov 20]
17. Nguyen-Kim L, Or Z, Paris V, et al. The politics of drug reimbursement in England, France, and Germany. IRDES Health Economics Letter 2005 Oct; 99 [online]. Available from URL: http://www.irdes.fr/EspaceAnglais/ Publications/IrdesPublications/QES099.pdf [Accessed 2008 Apr 16]
18. Paris V. Pharmaceutical regulation in France 1980-2003. Int J Health Plann Manage 2005; 20: 307-328
19. Mossialos E, Oliver A. An overview of pharmaceutical policy in four countries: France, Germany, the Netherlands and the United Kingdom. Int J Health Plann Manage 2005; 20: 291-306
20. Le Pen C. The drug budget silo mentality: the French case. Value Health 2003; 6 Suppl. 1: S10-9
21. Sandier S, Paris V, Polton D. Health care systems in transition: France. Copenhagen: WHO Regional office for Europe on behalf of the European Observatory on Health Systems and Policies, 2004 [online]. Available from URL: http://www. euro.who.int/document/e83126.pdf [Accessed 2008 Mar 6]
22. Paris V. Pharmaceutical regulation in France 1980-2003. Int J Health Plann Manage 2005; 20: 307-328
23. Couffinhal A, Paris V. Cost sharing in France: a working paper. 2003 Aug [online]. Available from URL: http:// www.irdes.fr/EspaceAnglais/Publications/ OtherPubs/Cost SharingInFrance.pdf [Accessed 2009 Nov 30]
24. Nouveaux cas des affections de longue durée (ALD 30) de 1990 à 2006: France entière [online]. Available from URL: http://www.ameli.fr/fileadmin/user-upload/documents/Tab leau-evolution-ald.pdf [Accessed 2008 Nov 20]
25. Legifrance. Social security code: article R-163-166 [online]. Available from URL: http://www.legifrance.gouv.fr/ affichCodeArticle.do?cidTexte= LEGITEXT000006073189 &idArticle=LEGIARTI000006747689&dateTexte=&cate gorieLien=cid [Accessed 2008 Nov 20]
26. ARCOBASE- (registered to the Agence pour la Protection des Programmes) [database; online]. Available from URL: http://www.arcosa.net/ [Accessed 2009 Nov 16]
27. Report on the activities of the Transparency Commission in 2004. Commission de la Transparence: 2005 Oct 10 [in French; online]. Available from URL: http://www.hassante. fr/portail/upload/docs/application/pdf/ctrapact2004. pdf [Accessed 2009 Feb 02]
28. Avis sur le médicament, adopté par le Haut Conseil pour l'Avenir de l'Assurance Maladie. Haut Conseil pour l'Avenir de l'Assurance Maladie: 2006 Jun 29 [online]. Available from URL: http://www.securite-sociale. fr/ institutions/hcaam/avis/hcaam-avis-060629.pdf [Accessed 2009 Feb 02]
29. Médicaments de la maladie d'Alzheimer: réévaluation à la baisse de l'amélioration du service rendu. Prescrire 2008 Mar 15 [online]. Available fromURL: http://www.prescrire. org/aLaUne/ dossierAlzheimerASMR.php [Accessed 2008 Nov 20]
30. Esomeprazole (Inexium): ASMR V et baisse de prix, enfin! Rev Prescrire 2009; 29 (313): 816 [online]. Available from URL: http://www.prescrire.org/ aLaUne/dossierEsome prazole.php [Accessed 2009 Dec 1]
31. Van Ganse E, Vukusic S, Zanetti L, et al. TYSEDMUS: cohort of multiple sclerosis patients treated with TYSAPRI using the French European database for multiple sclerosis (EDMUS)-methodological aspects. Pharmacoepidemiol Drug Saf 2008; 17: S1-294
32. French industry fed up with 'shortsighted' pharmaceutical policies [abstract]. Scrip 2006; 3198: 5
33. Office of Fair Trading (UK). The pharmaceutical price regulation system: an OFT study. Annexe K: international survey of pharmaceutical pricing and reimbursement schemes. London: The Office of Fair Trading, 2007 Feb [online]. Available from URL: http://www.oft.gov. uk/shared-oft/reports/comp-policy/ oft885k.pdf [Accessed 2009 Mar 6]
34. Arrêté du 18 avril 2003 modifant la liste des spé cialité s pharmaceutiques remboursables aux assuré s sociaux. Journal Officiel de la Rebublique Francaise 2003 Apr 19 [online]. Available from URL: http://www.sante.gouv.fr/ htm/actu/liste-smr.pdf [Accessed 2008 Nov 20]
35. Baisse du taux de remboursement de certains médicaments à SMR modéré ou faible [online]. Available from URL: http://www.sante.gouv.fr/htm/actu/31-030422.htm [Accessed 2008 Nov 20]
36. Naudin F, Sermet C. Drug delisting and reduced reimbursement: policy survey 2003 (2). Health Policy Monitor, Bertelsmann Stiftung's International Network for Health Policy and Reform [online]. Available from URL: http://www.irdes.fr/EspaceAnglais/Publications/ Medicines.html [Accessed 2009 Oct 30]
37. Anon. Document d'information générale réservé à l'usage de la presse 72 products removed [online]. Available from URL: http://www.sante.gouv.fr/htm/actu/medicament/ liste.pdf [Accessed 2008 Nov 20]
38. Third phase of French reimbursement cull begins. Scrip 2006; 3135: 6
39. Prise en charge des médicaments soumis à réévaluation-troisième vague de réévaluation des médicaments à service médical rendu insuffisant, les classes thérapeutiques concerne ́es 2006 [online].Available fromURL: http://www.hassante. fr/portail/jcms/c-456052/prise-en-charge-des- medicamen ts-soumis-a-reevaluation#c-456102 [Accessed 2008 Nov 20]
40. DISCOURS: '3ème vague de médicaments réé valué s' 2006 [online]. Available from URL: http://www.sante.gouv.fr/ htm/actu/33-061025xb.htm [Accessed 2008 Nov 20]
41. Simoens S, De Coster S. Sustaining generic markets in Europe. Leuven: Katholieke Universiteit Leuven, Research Centre for Pharmaceutical Care and Pharmacoeconomics, 2006 [online]. Available from URL: http://www. egagenerics.com/doc/simoens-report-2006-04.pdf [Accessed 2006 Oct 16]
42. Grandfils N. Implementation of reference prices: policy survey 2005 (6). Health Policy Monitor, Bertelsmann Stiftung's international network for health policy and reform [online]. Available from URL: http://www.irdes.fr/ EspaceAnglais/Publications/Medicines.html [Accessed 2009 Oct 30]
43. Simoens S. Trends in generic prescribing and dispensing in Europe. Expert Rev Clin Pharmacol 2008; 1 (4): 497-503
44. Decree n-2002-1216. Journal Officiel de la République française 2002 Sep 30: page 16260 [online]. Available from URL: http://www.droit.org/jo/2002/16260.html [Accessed 2008 Dec 10]
45. Spurgeon B. Opposition grows to new charges for drugs and ambulance trips. BMJ 2007; 335: 1228-1229
46. Chatel law. Les prix des médicaments remboursables sont les derniers prix industriels à être administré s 2008 [online]. Available from URL: http://www.leem.org/medica ment/les-prix-des-medicaments- remboursables-sont-les-derni ers-prix-industriels-a-etre-405.htm [Accessed 2008 Nov 20]
47. Kanavos P, Taylor D. Pharmacy discounts on generic medicines in France: is there room for further efficiency savings? Curr Med Res Opin 2007; 23: 2467-2476
48. Godman B, Haycox A, Schwabe U, et al. Having your cake and eating it: Office of Fair Trading proposal for funding new drugs to benefit patients and innovative companies. Pharmacoeconomics 2008; 26 (2): 91-98
49. AFSSAPS. Notice to applicants for temporary authorisation for use (ATU). May 2006 [online]. Available from URL: http://www.afssaps.fr/Activites/ Autorisations-temporai res-d-utilisation/ATU-Reglementation/(offset)/7 [Accessed 2008 Nov 20]
50. Notice to applicants for temporary authorisation for use (ATU). November 2007 [online]. Available from URL: http://www.afssaps.fr/var/afssaps-site/ storage/original/ application/32f7b4f77a894fa586797500dd52063c.pdf [Accessed 2009 Nov 30]
51. Launet O, Brouard A, Doreau C. Drugs under temporary use authorisation: 50 years of French drug development [in French]. Rev Hist Pharm (Paris) 2004; 52 (341): 47-54
52. ATU de cohorte en cours: spé cialité s, résumé s des caracte ́ristiques du produit (RCP) et notices destinées aux patients. October 2008 [online]. Available from URL: http://www.afssaps.fr/Activites/Autorisations-temporairesd- utilisation/ATU-de- cohorte/(offset)/2#paragraph-5196 [Accessed Nov 20 2008]
53. Or Z, de Pouvourville G. French hospital reforms: a new era of public-private competition? Eurohealth 2006; 12 (3): 21-23
54. Ré fé rentiels nationaux pour un bon usage des médicaments onéreux et innoVants April 2007 [online]. Available from URL: http://www.afssaps.fr/var/afssaps-site/storage/ original/application/ 16c927d47483c198c65af59667c14b57. pdf [Accessed 2009 Nov 30]
55. Falgarone G, Duclos M, Boissier M-C. TNF alpha antagonists in rheumatoid arthritis patients seen in everyday practice [editorial]. Joint Bone Spine 2007; 74: 523-526
56. Fautrel B, Pham T, L'Mouterde G, et al. Recommendations of the French Society for Rheumatology regarding TNF alpha antagonist therapy in patients with rheumatoid arthritis. Joint Bone Spine 2007; 74: 627-637
57. Allenet B, Barry H. Opinion and behaviour of pharmacists towards the substitution of brand products by generic drugs: survey of 1000 French community pharmacists. Pharm World Sci 2003; 25 (5): 197-202
58. Avis sur le médicament, adopté le 25 septembre 2008 par le Haut Conseil pour l'Avenir de l'Assurance Maladie. Haut Conseil pour l'Avenir de l'Assurance Maladie: 2008 Sep 25 [online]. Available from URL: http://www.securitesociale. fr/institutions/hcaam/avis/hcaam-avis-250908.pdf [Accessed 2009 Mar 1]
59. Godman B,Wettermark B, Hoffman M, et al. Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global releVance. Expert Rev Pharmacoecon Outcomes Res 2009; 9: 65-83
60. L'Assurance Maladie. Médicaments génériques: nouvelle progression du taux de penetration. 2007 Jul 5 [online]. Available from URL: http://www.ameli.fr/fileadmin/user- upload/documents/generiques-juil-2007. pdf [Accessed 2008 Feb 17]
61. L'Assuramce Maladie. Médicaments génériques: point d'étape à fin avril 2008 [online]. Available from URL: http:// www.ameli.fr/fileadmin/user-upload/documents/DP-generi ques-5-juin-08.pdf [Accessed 2008 Jul 11]
62. L'Assurance Maladie. Consommation et dépenses de médicaments: comparaison des pratiques françaises et européennes [online]. Available from URL: http://www. ameli.fr/fileadmin/user-upload/documents/Consommation- et-depenses-de- medicaments---Europe.pdf [Accessed 2008 Jul 7]
63. L'Assurance Maladie. La France championne d'Europe en dépenses de medicaments 2008 [online]. Available from URL: http://www.ameli.fr/fileadmin/ user-upload/docu ments/DP-La-France-championne-d-Europe-v2.pdf [Accessed 2008 Jul 7]
64. Rochaix L, Wilsford D. State autonomy, policy paralysis: paradoxes of institutions and culture in the French health care system. JHealth Polit Policy Law 2005; 30 (1-2): 97-119
65. Durieux P, Gaillac B, Giraudeau B, et al. Despite financial penalties, French physicians' knowledge of regulatory practice guidelines is poor. Arch Fam Med 2000; 9: 414-418
66. Pepin S, Ricordeau P. La consommation d'antibiotiques: situation en France au regard des autres pays Européens. L'Assurance Maladie 2006 Nov; 6 [online]. Available from URL: http://www.ameli.fr/fileadmin/user-upload/ documents/pointreperen-6.pdf [Accessed 2008 Feb 17]
67. L'Assurance Maladie. La maitrise medicalisee des depenses d'assurance maladie dans les deux-sevres. Bilan 2005/2006 et perspectives. 2006 Sep 28 [online]. Available fromURL: http://www.ameli.fr/fileadmin/user-upload/ documents/mai trise-medicalise.pdf [Accessed 2008 Jul 10]
68. L'Assurance Maladie. Programme antibiotiques: un premier cap est franchi, la mobilisation pour le bon usage doit se poursuivre. 2008 Jan 10 [online]. Available from URL: http://www.ameli.fr/fileadmin/user-upload/docu ments/DP-Antibiotiques-10-01-2008.pdf [Accessed 2008 Feb 17]
69. L'Assurance Maladie. Programme antibiotiques 2007/2008. L'Assurance Maladie repart en campagne sur les antibiotiques. 2007 Nov 27 [online]. Available from URL: http://www.ameli.fr/fileadmin/user-upload/documents/CP- campagne-antibiotiques-2007-2008.pdf [Accessed 2008 Feb 17]
70. L'Assurance Maladie. Maîtrise médicalisée des dépenses de santé : l'Assurance Maladie met en place un programme d'information des professionnels de santé . 2005 Mar 14 [online]. Available from URL: http://www.ameli.fr/fi leadmin/user-upload/documents/ cp14032005.pdf [Accessed 2008 Jul 10]
71. Chevreul K. Evaluation of professionals' practice. Policy survey 2005 (5). Health Policy Monitor for Bertelsmann Stiftung's International Network for Health Policy and Reform [online]. Available from URL: http://www.hpm. org/en/Surveys/IRDES---France/05/Evaluation-of-pro fessionals--practice.html? search=start+search&content-id= 251&sortOrdersortAsc&lastSortOrder= sortAsc&language =en&a=sh&search.x=46&sortBy=sortCountry&p- c:184=184 &p-i=0&search.y=9&lastSortBy=sortCountry&pageOffset =1 [Accessed 2008 Nov 20]
72. Or Z. A small step towards P4P in France. Health Policy Monitor, 2009 Apr [online]. Available from URL: http:// www.hpm.org/en/Surveys/IRDES---France/13/ A-small- step-towards-P4P-in-France.html?search=start+search &content-id=251&a=sh&search.x=68&p-c:184=184&p- i=0&language=en&search.y=11 [Accessed 2009 Dec 3]
73. Dourgnon D, Guillaume S, Naiditch M, et al. Introducing gate keeping in France: final assessment of the preferred doctor scheme reform. IRDES Issues in Health Economics 2007 Jul; 124 [online]. Available from URL: http://www. irdes.fr/EspaceAnglais/Publications/IrdesPublications/QES 124.pdf [Accessed 2008 Jan 5]
74. Cases C, Chevreul K, Meunier N, et al. Interview with Xavier Bertrand, French Minister of Health. Eurohealth 2006; 12 (3): 12-15
75. La couveture complementaire en France en 2006 [online]. Available fromURL: http://www.irdes.fr/EspaceEnseignement/ ChiffresGraphiques/ CouvertureComplementaire/Donnees Gnles/DonneesGnles.html [Accessed 2009 Mar 1]
76. LEEM. Les remboursements de l'ensemble des régimes de sécurité sociale [online]. Available from URL: http://www. leem.org/medicament/les-remboursements-de-l-ensembledes- regimes-de-securite- sociale-454.htm [Accessed 2009 Mar 1]
77. L'Assurance Maladie. Dépenses de médicaments en 2007: Quels sont les principaux moteurs de la croissance? [online]. Available from URL: http://www.ameli.fr/fileadmin/ user-upload/documents/Note-croissance- medicaments-2007. pdf [Accessed 2008 Jul 7]
78. Godman B, Bucsics A, Burkhardt T, et al. Insight into recent reforms and initiatives in Austria: implications for key stakeholders. Expert Rev Pharmacoecon Outcomes Res 2008; 8 (4): 357-371
79. Fattore G, Jommi C. The last decade of Italian pharmaceutical policy: instability or consolidation? Pharmacoeconomics 2008; 26 (1): 5-15
80. Motola D, De Ponti F, Rossi P, et al. Therapeutic innovation in the EU: analysis of the drugs approved by the EMEA between 1995 and 2003. Br J Clin Pharmacol 2004; 59: 475-478
81. MotolaD,De Ponti F, Poluzzi E, et al.An update on the first decade of the European centralized procedure: how many innovative drugs? Br J Clin Pharmacol 2006; 62: 610-616
82. AIFA-Italian Medicines Agency. Working Group on Innovative Drugs. Criteria for ranking therapeutic innovation of new drugs and elements for supplementing the dossier for admission to the reimbursement system (document approved by the AIFACTS on July 10, 2007) [online]. Available from URL: http://www.agenziafarmaco. it/allegati/integral-document.pdf [Accessed 2008 Nov 20]
83. European and French pharmaceutical market assessed by Prescrire in 2005: mainly bogus innovation [editorial]. Farmacia Hospitalaria 2006; 30 (2): 68-70
84. Garattini S, Bertele' V. How can we regulate medicines better. BMJ 2007; 335: 803-805
85. Addis A. An original research project. 2005 Dec 20 [online]. Available from URL: http://www.psocare.it/en-news letter-01.pdf [Accessed 2008 Feb 13]
86. Folino Gallo P, Deambrosis P. Pharmaceutical risk-sharing and conditional reimbursement in Italy. 2008 Nov [online]. Available from URL: http://www.ceestahc.org/ pliki/symp2008/gallo.pdf [Accessed 2009 Feb 20]
87. Wettermark B, Godman B, Andersson K, et al. Recent national and regional drug reforms in Sweden: implications for pharmaceutical companies in Europe. Pharmacoeconomics 2008; 26 (7): 537-550
88. Askling J, Fored CM, Geborek P, et al. Swedish registers to examine drug safety and clinical issues in RA. Ann Rheum Dis 2006; 65: 707-712
89. Lee T, Emanuel E. Tier 4 drugs and fraying of the social concept. N Engl J Med 2008; 359: 333-335
90. Gliklich RE, Dreyer NA, editors. Registries for evaluating patient outcomes: a user's guide (prepared by Outcome DEcIDE Center [Outcome Sciences, Inc. dba Outcome] under contract no. HHSA29020050035I TO1). AHRQ publication no. 07-EHC001-1. Rockville (MD): Agency for Healthcare Research and Quality, 2007 Apr
91. Taylor L. New UK PPRS includes 3.9% price cut, flexible pricing and generic substitution. 2008 Nov 20 [online]. Available from URL: http://www.eatg.org/eatg/New- UK-PPRS-includes-3.9-price-cut-flexible-pricing- and-genericsubstitution [Accessed 2009 Jan 4]
92. De Swaef A, Antonissen Y. Pharmaceutical pricing and reimbursement information, Belgium, 2007 Nov [online]. Available from URL: http://ppri.oebig.at/Downloads/ Results/Belgium-PPRI-2008.pdf [Accessed 2009 Jan 5]
93. Pudersell K, Vetka A, Rootslane L, et al., Pharmaceutical pricing and reimbursement information, Estonia June 2007 [online]. Available from URL: http://ppri.oebig.at/ Downloads/Results/Estonia-PPRI-2007.pdf [Accessed 2009 Jan 5]
94. Koppel A, Kahur K, Habicht T, et al. Estonia health system review.Health Syst Transit 2008; 10 (1) [online]. Available from URL: http://www.euro.who.int/ Document/E91372. pdf [Accessed 2009 Jan 5]
95. Ková cs T, Ró zsa P, Szigeti S, et al. Pharmaceutical pricing and reimbursement information, Hungary, 2007 Jun [online]. Available fromURL: http://ppri.oebig.at/Downloads/ Results/Hungary-PPRI-2007.pdf [Accessed 2009 Jan 5]
96. Teixeira I, Vieira I. Pharmaceutical pricing and reimbursement information, Portugal, 2008Oct [online].Available from URL: http://ppri.oebig. at/Downloads/Results/Portugal- PPRI-2008.pdf [Accessed 2009 Jan 5]
97. Godman B, Schwabe U, Selke G, et al. Update of recent reforms in Germany to enhance the quality and efficiency of prescribing of proton pump inhibitors and lipid-lowering drugs [research letter]. Pharmacoeconomics 2009; 27 (5): 435-438
98. Von Ferber L, Bausch J, Köster I, et al. Pharmacotherapeutic circles: results of an 18-month peer-review prescribingimprovement programme for general practitioners. Pharmacoeconomics 1999; 16 (3): 273-283
99. Mason AR, Drummond MF, Hunter JA, et al. Prescribing incentive schemes: a useful approach? Appl Health Econ Health Policy 2005; 4 (2): 111-117
100. Beishon J, McBride T, Scharaschkin S, et al. Prescribing costs in primary care. London: National Audit Office, 2007 May 18 [online]. Available from URL: http://www. nao.org.uk/publications/nao-reports/06-07/0607454.pdf [Accessed 2008 May 21]
101. Mason A. New medicines in primary care: a review of influences on general practitioner prescribing. J Clin Pharm Ther 2008; 33: 1-10
102. Atella V, Schafheutle E, Noyce P, et al. Affordability of medicines and patients' cost-reducing behaviour: empirical evidence based on SUR estimates from Italy and UK. Appl Health Econ Health Policy 2005; 4 (1): 23-35
103. Garattini L, Ghislandi S. Off-patent drugs in Italy: a shortsighted view? Eur J Health Econ 2006; 7: 79-83
104. Puig-Junoy J. Incentives and pharmaceutical reimbursement reforms in Spain. Health Policy 2004; 67: 149-165
105. Seeley E, Kanavos P. Generic medicines from a societal perspective: savings for healthcare systems? Eurohealth 2008; 14 (2): 18-22
106. Farmaci generici: dubbi o pregiudizi? Dialogo sui farmaci 2007; 2: 75-77
107. Wettermark B, Hammar N, Fored CM, et al. The new Swedish Prescribed Drug Register: opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf 2007; 16: 726-735
108. Malmvall B, Molstad S, Darelid J, et al. Reduction of antibiotics sales and sustained low incidence of bacterial resistance: report on a broad approach during 10 years to implement evidence-based indications for antibiotic prescribing in Jonkoping County, Sweden. Q Manage Health Care 2007; 16: 60-67
109. Arnold SR, Straus SE. Interventions to improve antibiotic prescribing practices in ambulatory care. Cochrane Database Syst Rev 2005; (4): CD003539
110. Cals JW, Boumans D, Lardinois RJ, et al. Public beliefs on antibiotics and respiratory tract infections: an internetbased questionnaire study. Br J Gen Pract 2007; 57: 942-947
111. Sahlan S, Wollny A, Brockmann S, et al. Reducing unnecessary prescriptions of antibiotics for acute cough: adaptation of a leaflet aimed at Turkish immigrants in Germany. BMC Fam Pract 2008; 9: 57 [online]. Available from URL: http://www.ncbi.nlm.nih.gov/pmc/articles/ PMC2577089/ [Accessed 2009 Nov 20]
112. Cars O, Högberg LD, Murray M, et al. Meeting the challenge of antibiotic resistance. BMJ 2008 Sep 18; 337: a1438 [online]. Available from URL: http://www.bmj.com/cgi/ content/full/337/sep18-3/a1438 [Accessed 2009 Nov 20]
113. Grigoryan L, Burgerhof JG, Degener JE, et al. Determinants of self-medication with antibiotics in Europe: the impact of beliefs, country wealth and the health care system. J Antimicrob Chemother 2008; 61: 1172-1179